Levocabastine

Drug Profile

Levocabastine

Alternative Names: Histimet; Levophta; Levostab; Livistin; Livocab; Livostin; R 50547

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen L.P.
  • Developer Janssen-Cilag; Kyowa Hakko Kirin; Nippon Shinyaku; Santen Pharmaceutical
  • Class Antiallergics; Piperidines; Sedating antihistamines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Allergic conjunctivitis; Seasonal allergic rhinitis

Most Recent Events

  • 01 Oct 2008 Kirin Pharma Company has merged with Kyowa Hakko to form Kyowa Hakko Kirin
  • 06 May 2008 Launched for Allergic conjunctivitis in European Union (Intraocular)
  • 06 May 2008 Launched for Allergic conjunctivitis in United Kingdom (Intraocular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top